Gates Foundation Grants Biotech Firm Aeras $220 Million Over 5 Years To Develop TB Vaccines

The Bill & Melinda Gates Foundation is “to give $220 million over five years to the non-profit biotech firm Aeras to develop vaccines to fight tuberculosis [TB], a company statement said Thursday,” Agence France-Presse reports (3/15). The “grant will allow Aeras to advance several vaccine candidates into pivotal large-scale efficacy trials in South Africa and elsewhere,” South Africa’s Health-e writes (Thom, 3/15). According to AFP, Aeras “has developed six possible TB vaccines that are being tested across Africa, Asia, Europe and America” (3/15).

“Aeras estimates a total of $400-500 million will be needed over the next five years to fund activities,” Health-e writes, noting, “The Gates grant provides approximately half of the estimated cost of meeting 2012 to 2016 milestone targets” (3/15). “Trevor Mundel, president of the global health program at the Bill & Melinda Gates Foundation, said the development of successful vaccines ‘would be the single greatest advance in the global fight against TB,'” AFP writes (3/15).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.